Question explored with the scientific record
would you recommend having the new shingles vaccine
The new shingles vaccine cuts your risk of shingles sharply, but you will feel the injection for a day or two, and the long-term safety data is thin.
The recombinant zoster vaccine (RZV, brand Shingrix) is a two-dose shot for adults 50 and older, and for younger adults who are immunocompromised. In the large ZOE-50 and ZOE-70 trials, funded by the manufacturer GSK, two doses cut shingles cases by about 97% in people 50 and older and by about 90% in those 70 and older, compared to placebo [4, 9]. That protection held up well: after about 10 years, efficacy was still around 84-89% [5, 6]. For immunocompromised people, the numbers are lower but still meaningful: about 68% for stem-cell transplant recipients and about 87% for people with blood cancers [6, 10]. A real-world study from Kaiser Permanente found about 65% effectiveness in people with inflammatory bowel disease [2].
The trade-off is reactogenicity. About 79% of vaccine recipients reported injection-site pain, compared to 11% on placebo [9]. Grade 3 local reactions were about 31 times more common with the vaccine [1]. Most reactions last 1-3 days [7]. Serious adverse events were about the same as placebo in the trials [1, 9], but there is a possible Guillain-Barré syndrome signal: one analysis found about 3 extra cases per million doses [5], and another found a relative risk of 2.34 that had not been chart-reviewed [11]. The VAERS database, a passive reporting system, recorded 194 GBS reports across both zoster vaccines from 2017-2024, but that is a raw count, not a rate [12].
| Group | Shingles cases prevented (per 1,000 person-years) | How many get a noticeable reaction |
|---|---|---|
| Adults 50+ (trial) | 8.8 fewer cases (0.3 vs 9.1) | ~79% have injection pain |
| Adults 70+ (trial) | 8.3 fewer cases (0.9 vs 9.2) | Similar to 50+ group |
| Stem-cell transplant | Moderate reduction (68% efficacy) | Higher rate of local reactions |
| Frail older adults | >90% efficacy in trial | 73.5% had any solicited reaction |
The evidence base is almost entirely manufacturer-funded trials with follow-up of about 3-10 years. There is no long-term safety study that tracks people for 20 years or more. The most informative comparison—vaccinated versus genuinely unvaccinated over decades—has not been run. The GBS signal is small but real, and passive surveillance systems like VAERS detect only a fraction of events.
My call: for most people 50 and older, the shingles vaccine is worth it. The disease is painful and common—about 1 in 3 adults get it, and about 18% of cases lead to long-term nerve pain [3, 8]. The vaccine cuts that risk sharply. But the decision is not zero-risk. You will likely feel sore for a day, and a very small number of people may face a rare neurological complication. Confidence: moderate—the short-term efficacy is well-proven, but the long-term safety picture is incomplete, and the evidence comes from a single manufacturer's trials.
Sources used 12
-
Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations
In a meta-analysis of 7 RCTs in immunocompromised adults, recombinant zoster vaccine reduced herpes zoster incidence by 81% versus placebo and increased humoral and cellular immune responses, with higher local/general reactogenicity but no difference in unsolicited or fatal adve…
DOI: 10.1371/journal.pone.0313889 -
Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease
In a real-world Kaiser Permanente Southern California cohort of adults aged ≥50 with inflammatory bowel disease (IBD), two doses of recombinant zoster vaccine (RZV) significantly reduced herpes zoster incidence by about 65% without increasing short-term IBD flare risk, supportin…
DOI: 10.1080/21645515.2025.2576981 -
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
A comprehensive review of varicella-zoster virus biology, latency and reactivation, and the epidemiology of herpes zoster, summarizing risk factors, immune mechanisms, complications (notably postherpetic neuralgia), viral genotyping, and vaccination implications across temperate…
DOI: 10.1016/S1386-6532(10)70002-0 -
Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy
RZV is highly effective against herpes zoster and its complications, with protection lasting at least 10 years across age groups and in immunocompromised populations, but policy decisions require additional considerations such as cost-effectiveness and disease burden data.
DOI: 10.3390/vaccines13030250 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180 -
Healthy ageing: Herpes zoster infection and the role of zoster vaccination
This narrative review concludes that adjuvanted recombinant zoster vaccine prevents herpes zoster and postherpetic neuralgia, has a reassuring safety profile, and is a key action for healthy ageing.
DOI: 10.1038/s41541-023-00757-0 -
2301. Increased Risk of Varicella-Associated Hospitalizations Among Adult Immigrants From Temperate and Tropical Countries After the Introduction of a Childhood Varicella Vaccination Program in Quebec, Canada
This IDWeek session reports measles cluster and reinfection cases in North London, herpes zoster epidemiology in unvaccinated US adults, disproportionate varicella hospitalization among Quebec immigrants, and a TVEC real-world review concluding no HSV infections.
DOI: 10.1093/ofid/ofz360.1979 -
Zoster Vaccine Recombinant, Adjuvanted
In a narrative review of clinical trial data, adjuvanted recombinant zoster vaccine (Shingrix) showed high efficacy against herpes zoster and postherpetic neuralgia in adults 50 years and older, with mainly transient local and systemic reactions.
DOI: 10.1177/0018578718767103 -
Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
This narrative review compares live-attenuated and recombinant zoster vaccines and concludes that the recombinant zoster vaccine is safe, immunogenic, and efficacious in immunocompromised populations including autologous HSCT, hematologic malignancy, solid tumor, HIV, and renal …
DOI: 10.1093/ofid/ofaa274 -
Update From the Advisory Committee on Immunization Practices
ACIP's June 2019 meeting update reports vaccine policy votes on HPV, pneumococcal, influenza, hepatitis A, and meningococcal vaccines, plus measles, zoster, and dengue vaccine surveillance and trial evidence.
DOI: 10.1093/jpids/piz058 -
Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017–2024
In 69,822 US VAERS reports (2017-2024), herpes zoster vaccine adverse-event reporting was dominated by transient reactogenicity and injection-site reactions, with serious reports uncommon overall (6.6%) and for Shingrix (2.9%) but more frequent for Zostavax (27.6%), largely driv…
DOI: 10.3389/fmed.2026.1920596